Type to search

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease | PTF
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma | Pharmtech Focus
RINVOQ ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis | Pharmtech Focus